The AMR Accelerator
The AMR Accelerator is an IMI Programme that comprises 9 projects with the shared goal of progressing the development of new medicines to treat or prevent resistant bacterial infections.
The AMR Accelerator aims to deliver up to 10 new preclinical candidates and 5 Phase II-ready assets by 2025.
With a wide-ranging series of antibacterial programmes the AMR Accelerator will enhance the overall pipeline of antibiotics to treat infections with M. tuberculosis, nontuberculous mycobacteria (NTM) and Gram-negative bacteria.
The AMR Accelerator is composed of three Pillars:
A Capability Building Network (the COMBINE and PrIMAVeRa projects) provides coordination and support across the Accelerator, and in addition has scientific goals to improve and standardise the animal models used in AMR research, and optimise clinical trial designs.
The Tuberculosis Drug Development Network (encompassing the ERA4TB and UNITE4TB projects) is working to accelerate the discovery of new combinations of drugs to treat tuberculosis.
The Portfolio Building Networks (the RespiriTB, RespiriNTM, TRIC-TB, GNA NOW and AB-Direct projects) support collaborative efforts to discover, develop and advance new and innovative antibacterial assets.
Learn more about the Accelerator Projects
AB-Direct
- 7 participants
- > 3.7 M€ budget
- 3 years. Started 1 July 2019
Antibiotic distribution and recovery in tissue
COMBINE
- 11 participants
- 25 M€ budget
- 6 years. Started 1 Nov 2019
Coordinate the AMR Accelerator projects
Research to strengthen scientific basis in the AMR field
ERA4TB
- 32 participants
- > 207 M€ budget
- 6 years. Started 1 Jan 2020
Development of anti-TB drug combinations
GNA NOW
- 12 participants
- > 31 M€ budget
- 6 years. Started 1 July 2019
New antibiotics to treat Gram-negative infections
RespiriNTM
- 9 participants
- > 8 M€ budget
- 6 years. Started 1 May 2019
Novel assets for non-tuberculous mycobacteria
RespiriTB
- 9 participants
- > 9.9 M€ budget
- 6 years. Started 1 May 2019
New assets for multidrug-resistant tuberculosis
TRIC-TB
- 2 participants
- > 8.3 M€ budget
- 4 years. Started 1 May 2019
Define a new place for Ethionamide in 1st-line TB treatments
UNITE4TB
- 29 participants
- 185 M€ budget
- 7 years. Started 1 June 2021
Accelerate the development of new treatment regimens for tuberculosis
Follow us:
| The AMR Accelerator has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreements No 853967 I 853989 I 853979 I 853932 I 853800 I 853903 I 853976. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. ERA4TB receives additional support from Global Alliance for TB Drug Development, Bill & Melinda Gates Foundation and University of Dundee. UNITE4TB receives additional support from Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research. https://www.imi.europa.eu/ |